Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
P/B ratio for Vor Biopharma Inc. (VOR)
P/B ratio as of 2023: 1.00
According to Vor Biopharma Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.00. At the end of 2022 the company had a P/B ratio of 1.05.
P/B ratio history for Vor Biopharma Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.00 |
| 2022 | 1.05 |
| 2021 | 2.00 |
| 2020 | 28.84 |
| 2019 | 182.20 |
| 2018 | -31.37 |